Open Journal Systems

An Analysis of Histamine 2 Receptor Antagonists and a Proposal for Lafutidine

Matthew Christopher Buchfellner

Abstract

On April 1^st, 2020, the Food and Drug Administration (FDA) made national headlines when it published a press release on the removal of Zantac, a popularly prescribed histamine-2 receptor antagonist in the United States. Due to this removal, and the subsequent fallout, it has become necessary to search for alternative H2RA's. Lafutidine, a marketed drug in Japan and India, has proven safety and efficacy as an H2RA option for the treatment of gastric ulcers and other gastrointestinal diseases. Larger scale clinical trials into Lafutidine use in the United States could solve problems that have arisen since the discontinuation of Zantac.

Keywords

Healthcare; Pharmacy; Global Health; FDA; Lafutidine; H2RA; PPI

References

FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. U.S. Food and Drug Administration. 2020 April 1. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market Accessed October 1st, 2020.

Shye R. Famotidine in Shortage Due to Heartburn Medication Recalls and COVID-19 Research. GoodRx. 2020 May 21. https://www.goodrx.com/blog/famotidine-shortage-from-heartburn-medication-recalls-and-covid-19-research/ Accessed October 1st, 2020.

A Review of Histamine Receptors. Tocris Bioscience. 2019 Jul 23. https://www.news-medical.net/whitepaper/20190723/A-Review-of-Histamine-Receptors.aspx Accessed October 1st, 2020.

Aguilera-Castro L, Prados-de-Argila-de-Martin C, Martinez-Albillos A. Practical considerations in the management of proton-pump inhibitors. University of Alcala. 2016 Mar; 108(3): 145-53. PubMed PMID: 26666270. https://online.reed.es/Revistas/REED_2016_108_3/Contenido/pdf/vol108num3_en_7.pdf Accessed October 1st, 2020.

Stogar (lafutidine) [package insert]. Tokyo, Japan: UCB Japan Co., Ltd.; Revised: April 2005. https://www.ucb.com/_up/ucb_com_products/documents/STOGAR-April2005(050414)_tcm62-3741_tcm81-8593.pdf Accessed October 1st, 2020.

Namikawa T, Munekage E, Maeda H, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014 Dec; 34(12): 7297-301. http://ar.iiarjournals.org/content/34/12/7297.long Accessed October 1st, 2020.

Shimatani T, Inoue M, Kuroiwa T et al. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 2006 Jan; 51(1): 114-120. PubMed PMID: 16416222. file:///C:/Users/Matthew%20Buchfellner/Downloads/Shimatani2006_Article_LafutidineANewlyDevelopedAntiu%20(2).pdf Accessed October 1st, 2020.

Tanaka M, Bamba M, Kamiko A et al. Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity. J of Japanese Pharmacol. 2001 Jun; 117(6): 377-86. PubMed PMID: 11436515. https://www.jstage.jst.go.jp/article/fpj/117/6/117_6_377/_article/-char/ja/ Accessed October 1st, 2020.

Isomoto H, Inoue K, Furusu H et al. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. WOL. 2003 March; 8(2): 111-119. PubMed PMID: 12662378. https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1523-5378.2003.00131 Accessed October 1st, 2020.

Ohara S, Haruma K, Kinoshita Y, Kusano M. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol. 2010 Dec;45(12):1219-27. doi: 10.1007/s00535-010-0283-8. Epub 2010 Jul 15. PMID: 20632193. Accessed October 1st, 2020.

Full Text: PDF

Article Level Metrics

Previous Years | Current Year